Having identified potential biomarkers of PI3K inhibition in pediatric glioblastoma cell lines, further validation will be best performed in an orthotopic model using an inhibitor that is a clinical candidate and crosses the blood-brain barrier. The gene discussed is PIK3CA; the disease is glioblastoma.